Search company, investor...

Sano Corporation

Stage

Other Investors | Acquired

About Sano Corporation

Delsys Pharmaceutical Corporation (acquired by Elan Corp. plc (NYSE: ELN)) Researcher and developer of dry powder handling technology for the development and manufacture of solid oral dosage forms of a number of drugs.

Headquarters Location

United States

Missing: Sano Corporation's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Sano Corporation's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Sano Corporation Patents

Sano Corporation has filed 1 patent.

The 3 most popular patent topics include:

  • Analytical chemistry
  • Electroanalytical methods
  • Electrochemistry
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/13/2020

4/5/2022

Disinfectants, Healthcare occupations, Antiseptics, Medical terminology, Microbiology

Grant

Application Date

8/13/2020

Grant Date

4/5/2022

Title

Related Topics

Disinfectants, Healthcare occupations, Antiseptics, Medical terminology, Microbiology

Status

Grant

Latest Sano Corporation News

Sano, que Adán Augusto López haya aclarado que no destapa candidatos: Miguel Barbosa

Oct 24, 2022

María Huerta Para el gobernador Miguel Barbosa Huerta, las candidaturas enMorena rumbo al 2024 se The post Sano, que Adán Augusto López haya aclarado que no destapa candidatos: Miguel Barbosa appeared first on desdepuebla.com.

Sano Corporation Frequently Asked Questions (FAQ)

  • What is Sano Corporation's latest funding round?

    Sano Corporation's latest funding round is Other Investors.

  • Who are the investors of Sano Corporation?

    Investors of Sano Corporation include Antares Capital Corporation and CenterPoint Ventures.

  • Who are Sano Corporation's competitors?

    Competitors of Sano Corporation include KIYATEC, Presage Biosciences, Milestone Pharmaceuticals, Rhenovia Pharma, Crossject Medical Technology and 12 more.

Compare Sano Corporation to Competitors

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Flamma Logo
Flamma

Flamma specializes in the manufacture of active ingredients and intermediates for the pharmaceutical, nutraceutical and cosmetic industries.

R
Rhenovia Pharma

Rhenovia Pharma is a French biotechnology company founded in 2007 by an international team that brings together managers from large pharmaceutical companies and world experts in neuroscience and nervous system modeling. The company is a provider in the application of biosimulation in the prevention and treatment of neurological, neurodegenerative and psychiatric disorders and diseases.

Presage Biosciences Logo
Presage Biosciences

Presage Biosciences is an oncology company that focuses on evaluating patient response to drugs in clinical trials. The company uses CIVO technology to deliver pharmacologically appropriate concentrations of multiple drugs to different regions of a tumor – while the tumor is still in the patient.

O
Optimata

Optimata Ltd. is a privately-owned science-based interdisciplinary company engaged in biosimulation technology for optimizing drug treatment protocols. Optimata partners with pharmaceutical and biotechnology companies to develop effective new treatments for diseases by simulating disease processes. This aims to reduce time-to-market and development costs while improving the competitive profile of the newly developed drug.

Q
QPS

QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.